Arenobufagin inhibits lung metastasis of colorectal cancer by targeting c-MYC/Nrf2 axis
Phytomedicine · 2024-05 · 127 · 155391
DOI: 10.1016/j.phymed.2024.155391 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2024-05. Verfasst von Mei Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, …. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Bufanolides, Lung Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zunyi Medical College.
Abstract (Originalsprache)
BACKGROUND: Colorectal cancer (CRC) is one of the commonest cancers worldwide. Metastasis is the most common cause of death in patients with CRC. Arenobufagin is an active component of bufadienolides, extracted from toad skin and parotid venom. Arenobufagin reportedly inhibits epithelial-to-mesenchymal transition (EMT) and metastasis in various cancers. However, the mechanism through which arenobufagin inhibits CRC metastasis remains unclear. PURPOSE: This study aimed to elucidate the molecular mechanisms by which arenobufagin inhibits CRC metastasis. METHODS: Wound-healing and transwell assays were used to assess the migration and invasion of CRC cells. The expression of nuclear factor erythroid-2-related factor 2 (Nrf2) in the CRC tissues was assessed using immunohistochemistry. The protein expression levels of c-MYC and Nrf2 were detected by immunoblotting. A mouse model of lung metastasis was used to study the effects of arenobufagin on CRC lung metastasis in vivo. RESULTS: Arenobufagin observably inhibited the migration and invasion of CRC cells by downregulating c-MYC and inactivating the Nrf2 signaling pathway. Pretreatment with the Nrf2 inhibitor brusatol markedly enhanced arenobufagin-mediated inhibition of migration and invasion, whereas pretreatment with the Nrf2 agonist tert‑butylhydroquinone significantly attenuated arenobufagin-mediated inhibition of migration and invasion of CRC cells. Furthermore, Nrf2 knockdown with short hairpin RNA enhanced the arenobufagin-induced inhibition of the migration and invasion of CRC cells. Importantly, c-MYC acts as an upstream modulator of Nrf2 in CRC cells. c-MYC knockdown markedly enhanced arenobufagin-mediated inhibition of the Nrf2 signaling pathway, cell migration, and invasion. Arenobufagin inhibited CRC lung metastasis in vivo. Together, these findings provide evidence that interruption of the c-MYC/Nrf2 signaling pathway is crucial for arenobufagin-inhibited cell metastasis in CRC. CONCLUSIONS: Collectively, our findings show that arenobufagin could be used as a potential anticancer agent against CRC metastasis. The arenobufagin-targeted c-MYC/Nrf2 signaling pathway may be a novel chemotherapeutic strategy for treating CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi 563000, PR China.
- Department of Pathophysiology, Zunyi Medical University, Zunyi 563000, Guizhou, PR China.
- Department of Pathophysiology, Zunyi Medical University, Zunyi 563000, Guizhou, PR China. Electronic address: hailongzhao@zmu.edu.cn.
- Guizhou Provincial College-based Key Laboratory for Tumor Prevention and Treatment with Distinctive Medicines, Zunyi Medical University, Zunyi, 563000, PR China. Electronic address: liuyunzmu@126.com.
- Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi 563000, PR China. Electronic address:…
Förderung
- Zunyi Medical College
Zitieren
APA
Wang, M., Hu, S., Yang, J., Yuan, L., Han, L., Liang, F., Zhang, F., Zhao, H., Liu, Y., & Gao, N. (2024). Arenobufagin inhibits lung metastasis of colorectal cancer by targeting c-MYC/Nrf2 axis. Phytomedicine, 127, 155391. https://doi.org/10.1016/j.phymed.2024.155391
Vancouver
Wang M, Hu S, Yang J, Yuan L, Han L, Liang F, et al. Arenobufagin inhibits lung metastasis of colorectal cancer by targeting c-MYC/Nrf2 axis. Phytomedicine. 2024;127:155391. doi:10.1016/j.phymed.2024.155391
BibTeX
@article{Wang2024,
author = {Wang, Mei and Hu, Siyi and Yang, Jiawang and Yuan, Liang and Han, Limin and Liang, Feng and Zhang, Fenglin and Zhao, Hailong and Liu, Yun and Gao, Ning},
title = {Arenobufagin inhibits lung metastasis of colorectal cancer by targeting c-MYC/Nrf2 axis},
journal = {Phytomedicine},
year = {2024},
volume = {127},
pages = {155391},
doi = {10.1016/j.phymed.2024.155391}
}
EUVIMED